This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Administration of Recombinant Human Leukocyte 2-Interferon in Patients With Amyotrophic Lateral Sclerosis

Marinos C. Dalakas, MD; Allen J. Aksamit, MD; David L. Madden, PhD; John L. Sever, MD, PhD

Arch Neurol. 1986;43(9):933-935.

Abstract
• Recombinant leukocyte ₂-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.

Author Affiliations
From the Infectious Diseases Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Md.

Footnotes
Accepted for publication May 19, 1986.

Reprint requests to Bldg 36, Room 5D06, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 (Dr Dalakas).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of High-Dose Intravenous Immunoglobulin on Amyotrophic Lateral Sclerosis and Multifocal Motor Neuropathy
Dalakas et al.
Arch Neurol 1994;51:861-864.
ABSTRACT  

Amyotrophic Lateral Sclerosis: Recent Advances in Pathogenesis and Therapeutic Trials
Mitsumoto et al.
Arch Neurol 1988;45:189-202.
ABSTRACT